ARK’s CRISPR Sale: Timing the Market’s Mood

Now, I’ll admit I’ve never owned a single share of CRISPR. My own portfolio resembles a thrift store bin-lots of mystery, minimal value-but I do understand the agony of watching something you love underperform. Take CRISPR’s stock price: up 0.64% over the past year while the S&P 500 zoomed past it like a Tesla on Autopilot. It’s the financial equivalent of being left at the prom while your date goes home with a blockchain ETF.




